Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8314 results

  1. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

    Awaiting development Reference number: GID-TA10453 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development Reference number: GID-TA11300 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development Reference number: GID-TA11404 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Leriglitazone for treating andrenoleukodystrophy [ID3903]

    In development Reference number: GID-TA11445 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

    Awaiting development Reference number: GID-TA10604 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development Reference number: GID-TA10605 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

    In development Reference number: GID-TA10606 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

    Awaiting development Reference number: GID-TA10657 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Nitisinone for treating alkaptonuria [ID2691]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Sotagliflozin for treating type 2 diabetes [ID1657]

    Awaiting development Reference number: GID-TA10665 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Remimazolam for general anaesthesia [ID3796]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development Reference number: GID-TA10773 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development